Cost-effectiveness Analysis of Furmonertinib Compared to Gefitinib in First-line Monotherapy for Advanced Non-small Cell Lung Cancer with EGFR Mutation

SU Guangquan, YI Renping, FANG Pingping, XIA Yimiao, PAN Min, GE Kunkun, SHEN Aizong

Herald of Medicine ›› 2024, Vol. 43 ›› Issue (8) : 1245-1251.

PDF(9843 KB)
中国科技论文统计源期刊　中文核心期刊  
美国《化学文摘》《国际药学文摘》
《乌利希期刊指南》
WHO《西太平洋地区医学索引》来源期刊  
日本科学技术振兴机构数据库（JST）
第七届湖北十大名刊提名奖  
PDF(9843 KB)
Herald of Medicine ›› 2024, Vol. 43 ›› Issue (8) : 1245-1251. DOI: 10.3870/j.issn.1004-0781.2024.08.012

Cost-effectiveness Analysis of Furmonertinib Compared to Gefitinib in First-line Monotherapy for Advanced Non-small Cell Lung Cancer with EGFR Mutation

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2024, 43(8): 1245-1251 https://doi.org/10.3870/j.issn.1004-0781.2024.08.012

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(9843 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉